Clinical Trial Modernization: Optimizing The Supply Of Decentralized Studies

The global COVID-19 pandemic has had a significant impact on all our lives, forcing us to adapt and find creative ways to continue our day-to-day lives. Clinical trials are no exception and have had to face many new challenges. Due to local lockdowns, patient and site staff safety, and personal choice, some patients have been unable or unwilling to travel to their clinical site and in some cases, clinical sites have had to close completely. Clinical sites and sponsors have had to quickly implement solutions and Biopharma companies are heeding the call to innovate, be agile, reduce waste and, most of all, achieve patient centricity. This new way of life provides an opportunity for the further decentralization of clinical trials, with direct-to-patient (DTP) reducing or eliminating the need for patients to travel to clinical sites and potentially expose themselves and others to a risk of infection.